Trial Profile
A randomized, placebo-controlled, three-part phase I single-ascending dose study of DS-1040 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2017
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary)
- Indications Pulmonary embolism; Stroke
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company
- 24 Feb 2017 New trial record
- 17 Feb 2017 Results published in the Journal of Thrombosis and Haemostasis